Clinical Trial

Study SARS-CoV-2-CZ-PREVAL-II - Arm of the Olomouc Region

Name: Study SARS-CoV-2-CZ-PREVAL-II - Arm of the Olomouc Region — clinical trial record (NCT07387211)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Completed

View on ClinicalTrials.gov →

Summary

The aim of the study is to find the proportion of people in the population of the Olomouc Region with the presence of IgG (or IgM) antibodies against the S and N antigens of the SARS-CoV-2 virus, therefore people who have already encountered the SARS-CoV-2 virus with manifest antibody formation, or people who have undergone vaccination against COVID-19.

Trial Details

NCT Number	NCT07387211
Lead Sponsor	The Institute of Molecular and Translational Medicine, Czech Republic Collaborators: Palacky University, University Hospital Olomouc
Conditions	SARS-CoV-2, SARS-CoV-2 (COVID-19) Infection
Enrollment	2,484 participants
Start Date	2022-01-18
Primary Completion	2022-10-13 (estimated)
Study Completion	2022-10-13 (estimated)
Updated on ClinicalTrials.gov	2026-02-04